AbsTrACT
Objective Mutations in cell-free circulating Dna (cfDna) have been studied for tracking disease relapse in colorectal cancer (crc). this approach requires personalised assay design due to the lack of universally mutated genes. in contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer-specific methylated biomarkers which could be measured longitudinally in cfDna (liquid biopsy) to monitor therapeutic outcome in patients with metastatic crc (mcrc). Design genome-wide methylation microarrays of crc cell lines (n=149) identified five cancer-specific methylated loci (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Digital Pcr assays were employed to measure methylation of these genes in tumour tissue Dna (n=82) and cfDna from patients with mcrc (n=182). Plasma longitudinal assessment was performed in a patient subset treated with chemotherapy or targeted therapy. results Methylation in at least one marker was detected in all tumour tissue samples and in 156 mcrc patient cfDna samples (85.7%). Plasma marker prevalence was 71.4% for EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 69.1% for MAP3K14-AS1% and 65.1% for MSC. Dynamics of methylation markers was not affected by treatment type and correlated with objective tumour response and progression-free survival. Conclusion this five-gene methylation panel can be used to circumvent the absence of patient-specific mutations for monitoring tumour burden dynamics in liquid biopsy under different therapeutic regimens. this method might be proposed for assessing pharmacodynamics in clinical trials or when conventional imaging has limitations.
InTrODuCTIOn
Tumours release fragments of nucleic acids into circulation, which could provide a minimally invasive surrogate for tissue biopsy as well as offering the opportunity of serial sampling over time. 1 2 Recent liquid biopsy studies have evaluated tumour-specific mutations or gene copy number changes in cell-free circulating DNA (cfDNA) derived from patients with digestive tract cancer for early diagnosis 3 and for monitoring the emergence of disease relapse. 1 4-7 This approach usually relied on alterations in oncogenic drivers such as RAS and BRAF-up to 50% of the colorectal cancer (CRC) population-or mutations within oncosuppressor genes (usually with no variant hotspots), therefore requiring specific assay design for each mutation. Studies mainly focused on follow-up after surgery 5 6 8 or on patients with CRC treated with epidermal growth factor receptor (EGFR) targeted therapies, 4 9 10 in which detection of oncogenic RAS alterations is associated with impaired treatment response.
Changes in epigenetic patterns are often associated with alterations in physiological or pathological conditions triggering cell death and release of DNA with specific epigenetic marks, 11 which prompted exploring liquid biopsy tests as a surrogate of liver fibrosis severity in individuals affected by non-alcoholic fatty liver disease. 12 Changes in DNA methylation are considered an early event in carcinogenesis 13 and have already been proposed for early tumour detection in different settings (including CRC), allowing non-invasive population screening using stool 14 15 or blood. [16] [17] [18] [19] [20] [21] The Food and Drug Administration recently approved the first blood test exclusively based on SEPT9 methylation, which might lead to improvements in CRC screening uptake. 16 17 Here we propose the evaluation of DNA methylation markers in cfDNA, not as an early detection method, but rather as a non-invasive treatment-monitoring assay.
Review of methylation markers for early detection of CRC identified genes which were highly tumour specific (not found in normal adjacent mucosa), but rarely validated in large cohorts. 22 While using innovative approaches and being very informative, studies which aimed at identifying cancer-specific methylated markers usually relied on platforms with low genomic coverage, 21 or small sample datasets, 23 or exclusively assessed patient tissue 18 24 which might have been partially infiltrated with stroma. We therefore employed genome-wide assessment of DNA methylation in a large collection of 149 CRC cell lines and identified a five-gene panel that was validated in tissue and cfDNA from patients with metastatic CRC (mCRC) using digital PCR-based assays (methyl-BEAMing 19 25 ). Longitudinal assessment of this panel in cfDNA was performed to monitor disease burden in patients with mCRC over diverse treatment courses.
MATerIAls AnD MeTHODs
Additional details are available in online supplementary file 1.
Cell lines and genome-wide DnA methylation data processing and retrieval
A collection of 149 cell lines of intestinal origin (see online supplementary file 2A) was assembled, as described. 26 Infinium HumanMethylation450 BeadChip arrays were prepared according to manufacturer's protocol. Cell line methylation profiles are available on Gene Expression Omnibus (http:// www. ncbi. nlm. nih. gov/ geo/; accession number: GSE86078). After removing ulcerative colitis cases, cancer unrelated normal mucosa samples from GSE32146 were used as a control set. GSE41169 was employed as a blood control dataset (ie, healthy donors). GSE42752 23 was used as a test cohort for establishing an in silico validation threshold. Level 1 data from the TCGA colorectal adenocarcinoma (COAD/READ) (https:// gdc-portal. nci. nih. gov) were used for the in silico validation. Further validation in normal tissues was performed using GSE48684. 24 
Data preprocessing and marker discovery analysis
All raw data (IDAT files) were preprocessed in R Bioconductor (minfi 27 ). Probe signal was removed when the detection p value was above 0.05, or >1% of the dataset contained no data, or if probes contained single nucleotide polymorphisms, 28 demonstrated sexual dimorphism 29 or were located on sex chromosomes. Our dataset was then merged with the other publicly available cohorts.
Differential methylation analysis was performed at probe (lmFit from limma; adjusted p≤1×10 -35 ; minimum delta beta-value of 0.8) or region level (bumphunter from minfi; threshold=0.8; regions represented by at least two probes with L≥2). Methylation in leucocytes was excluded (GSE41169; maximum beta-value allowed=0.1) to minimise the risk of false positivity in blood tests. Differentially methylated probes were limited to those overlapping differentially methylated regions, and 'liquid biopsy' assessable loci were defined as regions represented by at least two selected probes distant of a maximum 150 bp, the average fragment size reported in cfDNA 30 and not located in centromeres or telomeres (see online Supplementary file 2B).
Receiver operating characteristic analyses were performed in GSE42752 with the pROC package in R Bioconductor 31 to establish thresholds, considering normal and adjacent mucosa as positive outcome and cancer as negative; only loci showing a threshold below 0.35 were kept. Each threshold was used to stratify the TCGA COAD/READ cohort, defining a positive predictive value (PPV) and negative predictive value (NPV) for discriminating normal adjacent from tumour tissue. Normal healthy and peritumoural samples from GSE48684 24 were also controlled for absence of methylation above the threshold. All data used for the in silico analyses were from DNA derived from fresh frozen samples.
Methylation and genetic alteration assays for cfDnA evaluation
Assays were designed and optimised as described 25 to allow methylation independent amplification. Full details are given in online supplementary file 2C and 3. In silico validation was performed using solely the probes which were located within the amplicon; results for the five markers of interest are displayed in online supplementary file 4.
Evaluation of genetic alterations (KRAS, BRAF mutations and MET gene copy number) in cfDNA was performed as reported. 4 32 Assays, commercially available (Bio-Rad), are listed in online supplementary file 2C.
Tissue collection and DnA isolation
Formalin-fixed paraffin-embedded (FFPE) tissues originated from two different cohorts. The first consisted of macro-dissected tumour and normal adjacent tissues (n=31 cases; originating from several local hospitals), which were controlled for tumour purity and assembled at Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda (Milan, Italy) and from which DNA Colon Figure 1 Workflow of the study. A multistep marker discovery analysis was first performed to identify highly prevalent cancer-specific markers. After design, assay probes were further validated in silico. Assays were optimised to achieve linear quantification over a wide methylation range (0.09%-100%). Marker prevalence was first evaluated in tissue samples from 82 subjects with CRC. Then marker prevalence was evaluated in cfDNA in a total of 232 donors enrolled in the study among which 50 were de-identified self-declared healthy donors, and 182 patients with mCRC. Among mCRC cases, 45 were followed longitudinally and treated either with conventional chemotherapy, targeted therapy regimen or with temozolomide (TMZ) as part of a clinical trial. Methylation was analysed longitudinally for cases with positivity in at least one marker at baseline sample. Methylation dynamics was then compared with additional available clinical or molecular features. In green: unpublished data; in blue: bench experiments; in orange: bioinformatics or statistical analyses with clinical correlates; in grey: sample exclusion. *GSE32146 was used after removal of ulcerative colitis cases. **In silico validation was performed again restricting the analysis to the probes included in the assay amplicon. ***Only normal healthy and peritumoural tissues were used from GSE48684.
was newly extracted (average DNA concentration: 689 ng/µL (59-1844)). A second dataset of independent FFPE tumour tissues (n=51) was assembled from remaining DNA extracted during the enrolment of the DETECT-01 (EudraCT number 2011-002080-21) 33 or TEMECT (EudraCT number 2012-003338-17) 34 trials (average DNA concentration: 163 ng/µL (10-776)).
Plasma collection and DnA isolation
De-identified plasma samples (average volume 1.5 mL (0.8-1.9)) from self-declared healthy donors (n=50) were purchased from the Brigham and Women's Hospital specimen bank (Boston, USA).
One hundred and eighty-two mCRC cases were retrospectively enrolled in the study. One hundred and thirty-seven cases were selected for plasma time-points based on blood sample availability at a time when patients were presenting radiological evidence of disease. The remaining 45 cases were treatment baseline specimens, selected for availability of longitudinal follow-up samples (additional total of 132 longitudinal samples). The plasma volume obtained from patients with mCRC for the study was on average 1 mL (0.5-1.4). Summary of the clinicopathological features of the two cohorts can be found in online supplementary file 2D and patient clinical features are presented in online supplementary file 2E. mCRC plasma samples were collected at Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda (Milan, Italy) or at San Giovanni Battista Hospital (Turin, Italy). The study was conducted according to Good Clinical Practices and was approved by the local ethics committee. Circulating DNA was extracted as previously described 25 from 1 mL of plasma or less due to limited amount availability.
statistics and data analyses
All methylation microarray analyses and figures were generated in R Bioconductor as previously mentioned. Prevalence and longitudinal representations were assembled in GraphPad. Wilcoxon test (for matched tissues analysis), Mann-Whitney U test and Kruskall-Wallis test (for group prevalence analyses) and Mantel-Cox log rank test (for survival analysis) were performed in GraphPad. Scatter matrix for marker correlation was obtained using OriginPro 2016 (OriginLab). All expressed p values were calculated with two-tailed tests and were considered significant when p≤0.05, unless otherwise specified. of a larger genomic region controlled to be unmethylated in blood cells which represent the main contaminant source of cfDNA (figure 1, Supplementary file 2B and 5). Among the markers previously proposed for liquid biopsy assessment of CRC, SEPT9 was discarded for few differentially methylated probes too distant from each other; WIF1 was removed because of low differential methylation between normal and tumour tissue; while NPY demonstrated positivity in normal mucosa samples and blood cells (see online supplementary file 6). Thirty-nine loci defined by 93 probes, were selected as liquid biopsy assessable regions (see online supplementary file 5). An in silico validation (see online supplementary file 4), confirmed that the selected methylated loci were cancer specific and not a consequence of cell line establishment and identified six loci (five genes: EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC) capable of discriminating cancer from normal mucosa with a PPV of 1 and a NPV above 0.5. Short methylation independent amplification was considered feasible for the five genes. Digital PCR (Methyl-BEAMing) assays were designed and their sensitivity and specificity were reassessed in silico using the probes located within the amplicon (see online supplementary file 4). The quantitative aspect of the assay was privileged over sensitivity, for better serving the purpose of monitoring tumour burden in advanced disease patients. Digital MIQE checklist can be found in online supplementary file 3.
Assessment of methylation markers in tissue from patients with CrC
Methylation status was evaluated in FFPE tissue DNA for the five markers defined above (EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC). Amplification was successful in all cases.
Significantly higher methylation levels were observed in tumour tissue compared with their normal counterpart (p<0.0001), and remained high in an independent set of non-macro-dissected tumour specimens (figure 2). Average methylation (and range) for normal tissues was 0.6% (0-3), 7.9% (0-28), 0.5% (0-9), 0.3% (0-2) and 2.3% (0-12) for EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC, respectively. Average methylation (and range) for matched tumour tissues was 42.2% (0-92), 67.1% (18-97), 51.7% (2-96), 43.5% (0-97) and 71.5% (31-97) for EYA4, GRIA4, ITGA4, MAP3K14-AS1, MSC, respectively.
Detection of methylation markers in cfDnA of healthy individuals and patients with CrC
Plasma samples were obtained from a cohort of self-declared healthy individuals deliberately chosen above age 40 (n=50), and from a cohort of patients with mCRC (n=182). Methylation status was evaluated in a total of 364 cfDNA samples for the five markers ( Figure 1 and online supplementary file 2G). Amplification was successful in all samples but one for GRIA4 (0.3%), four cases for ITGA4 (1.1%) and seven for MSC (1.9%) (online supplementary file 2G).
Marker prevalence in cfDnA
Considering only non-longitudinal mCRC samples from individual patients for prevalence purpose (figure 1), all markers showed significant differences in methylation distribution between self-declared healthy donors and patients with mCRC (U test: p<0.0001, Figure 3A -E and online supplementary file 2G). Average methylation (and range) for self-declared healthy donors was 0.5% (0-7. Receiver operating characteristic curve (ROC) analyses were performed for each marker in order to evaluate their performance and establish a clinically relevant positivity threshold to discriminate self-declared healthy donors from patients with mCRC (see online Supplementary file 7). Cut-off values were 0.7% for EYA4, 0.79% for GRIA4, 1.06% for ITGA4, 0.24% for MAP3K14-AS1, 0.9% for MSC and 0.68% when averaging the five markers. Only two plasma samples from healthy donors showed an average methylation above the threshold ( Figure 3G ). This was due to high methylation values in GRIA4 and EYA4 for one individual (aged 43 years), and in EYA4 for the second (aged 62 years). One hundred and thirty-nine (76%) patients with mCRC displayed an average methylation above the threshold. Positivity, defined as the methylation value over cut-off thresholds and number of methylated events above the limit of blank (LOB), was observed in 71.4% for EYA4, 68.5% for GRIA4, 69.7% for ITGA4, 68.1% for MAP3K14-AS1, 65.1% for MSC, respectively. Considering that positivity in a single marker would be enough to track tumour burden, we evaluated that 156 cases (86%) showed positivity in at least one marker. When methylation values were positive, all markers were correlated (figure 3H and online Supplementary file 8). Total DNA amount assessed by genome equivalent per millilitre also significantly discriminated self-declared healthy donors from patients with mCRC, although with lower specificity ( Figure 3F and online Supplementary file 7).
Marker prevalence in tumour tissue and matched metachronous cfDnA samples
Tumour tissue DNA and matched metachronous cfDNA samples were available for a small subset of patients for which primary tumour had been resected (n=39). Marker negativity in cfDNA 
Association between cfDnA methylation and clinicopathological features
Using univariate analyses, age, treatment status and BRAF or RAS oncogenic mutations were not associated with different methylation values (see online Supplementary file 10; Supplementary file 2). High carcinoembryonic antigen (CEA) level (>5 ng/mL) showed a non-significant trend for higher methylation values in cfDNA (p=0.11). Male gender was significantly associated with lower methylation values (p=0.029), while the presence of unresected primary tumour (p=0.002), bulky disease (defined as massive tumour involvement of >50% of liver or lungs; p=0.012) or multiple metastatic lesions (p=0.023) were significantly associated with higher methylation values. The sum of target lesions as per Response Evaluation Criteria for Solid Tumours (RECIST) 35 from available CT scans was also associated with high methylation in the highest quartiles. Altogether these findings strongly suggest an association between release of methylated cfDNA and tumour burden.
longitudinal assessment
Among the 182 patients with mCRC, 45 were followed-up longitudinally ( figure 1) ; of those, seven were excluded due to absence of any positive marker at baseline (n=6) or inadequate follow-up (n=1). Methylation changes, between baseline and longitudinal plasma samples (obtained within 20 days from the first radiological evaluation) were annotated with the tumour response status to therapy (see online Supplementary file 11). Significant lower methylation values were detected in samples collected close to radiological assessment of clinical benefit (defined as objective disease stabilisation or partial response as per RECIST criteria) for all markers but EYA4. In comparison, samples collected close to documented objective tumour progression showed a non-significant trend towards increased methylation values for all markers. This suggests that cfDNA methylation changes could be associated with tumour burden dynamics. Therefore, we investigated whether longitudinal follow-up of methylation could track tumour burden over time. For this purpose, for each longitudinal timepoint an average of selected markers (ASM) was calculated based exclusively on the loci which displayed positive methylation in the baseline.
Monitoring of mCrC response to conventional chemotherapy
Ten cases received conventional chemotherapy regimens (FOLFOX, FOLFIRI, with or without bevacizumab). Two cases were excluded because they were negative at baseline. All patients carried KRAS or BRAF mutated tumours (considered as early events in tumourigenesis) allowing correlative assessment with methylation (figure 4). ASM was used for longitudinal monitoring. For most time-points, ASM dynamics recapitulated tumour burden changes as assessed by imaging, with a decrease preceding partial response or stable disease, while an increase or stable ASM anticipated progression. For all cases with known mutations in the corresponding tissue, KRAS or BRAF mutant levels in cfDNA paralleled the ASM. At a few time-points negative for mutation detection and displaying low DNA amount, ASM was around 1%, which Colon Figure 5 Average of selected markers (ASM) in cell-free circulating DNA dynamics in five metastatic colorectal cancer (CRC) patients treated with panitumumab for whom resistance causative mutations were discovered at progression and retrospectively assessed longitudinally. (A-C): Resistance was acquired through the emergence of a KRAS alteration; (D): resistance was acquired through the emergence of MET gene amplification. In each case, increase in ASM parallels the appearance of resistance alterations. (E): A case in which resistance mechanism remained unidentified but for which ASM could detect relapse.
could reflect either higher sensitivity of multiple methylated marker testing or possible overestimation of the current assays (see online Supplementary file 12).
Monitoring of mCrC response to targeted therapy
Additional six cases with longitudinal follow-up were treated with the EGFR targeted antibody panitumumab based on RAS wild-type status (figure 1). One case displaying a baseline sample negative for methylation was excluded. Four out of five cases (figure 5) demonstrated emergence of a resistance causative alteration at progression which could be retrospectively analysed over time. In three individuals, progression was associated with the emergence of KRAS alterations (figure 5A-C), 4 in one by MET gene amplification 32 ( figure 5D ). In all cases, ASM increased in parallel with the emergence of the resistance causative alteration. However, ASM values in plasma were much more abundant than the percentage of mutant KRAS alleles in two cases. In two patients, panitumumab was followed at progression by standard chemotherapy (irinotecan) that was associated with decrease of KRAS cfDNA level independently of the methylation dynamics. The remaining case for which the molecular mechanism of resistance to EGFR target therapy remained unexplained could still be monitored in cfDNA with an increase in the ASM value at progression (figure 5E).
Application of methylated circulating DnA monitoring in a clinical trial with temozolomide in chemorefractory mCrC with MGMT hypermethylation
We investigated the use of methylated cfDNA in 29 cases from the TEMECT trial (EudraCT number 2012-003338-17), which assessed efficacy of temozolomide treatment in patients with chemorefractory mCRC selected based on their O-6-methylguanine-DNA methyltransferase (MGMT) methylated status in the primary tumour tissue. 34 Three cases without any positive methylated marker at baseline and one case without longitudinal collection were excluded (figure 1). To explore whether methylated markers in liquid biopsy could be used as a surrogate to imaging, we considered the best methylation change over time, similarly to what is usually performed with imaging-based RECIST criteria. To this aim, the ASM at a longitudinal timepoint was subtracted from the ASM value at baseline, and the best methylation change (lowest) over the course of treatment was selected for correlative assessment with radiological response (see online supplementary file 2I). A decrease in methylation was associated with clinical benefit as evaluated by RECIST (stable disease or partial response; figure 6A, PPV=0.82; NPV=0.79, p=0.0048). Considering the best ASM change over time, a decrease in ASM was associated with improved progression-free survival (p=0.039, HR relapse =0.48 (0.17-0.87); figure 6B ).
DIsCussIOn
The current use of imaging for follow-up in CRC suffers from limitations potentially leading to overtreatment, delays in treatment reorientation and potential side effects of exposure to imaging contrast agents. The evaluation of serum protein levels such as CEA offers a rapid and cost-effective way to measure disease evolution, but is impaired by limited sensitivity and specificity, the latter especially during treatment courses due to inflammation and release of protein in the bloodstream. 36 Furthermore, a fraction of patients with mCRC does not show detectable plasmatic CEA levels during the natural history of the disease. 37 Longitudinal evaluation of cancer-specific mutations Colon in cfDNA has been exploited to identify relapse after surgery 5 or during treatment with both standard chemotherapies and targeted agents, 1 4 and it demonstrated great specificity and sensitivity. However, these studies must rely on either mutational hotspots with partial prevalence (only up to 50% considering all alterations of KRAS and BRAF) or on personalised assay design after identification of a variant through massive parallel sequencing. 4 5 Alterations in methylation patterns present an advantage, as they are limited to specific regions of the genome, allowing for a universal assay design compatible for population studies. Moreover, their prevalence is usually high, which triggered their implementation as early diagnostic assays. 38 We confirmed the proof-of-concept work from Garrigou et al 39 that DNA methylation in cfDNA may be employed to track response during therapy in mCRC, enabling non-invasive monitoring of tumour burden. To go beyond previous efforts in this area, we decided to perform a marker discovery analysis using CRC cell lines. This strategy allowed removal of background signal coming from stroma, which has recently been described to impair cancer signal specificity in genome-wide analyses. 40 Further validation in independent cohorts (in silico) or in tissue samples confirmed that these markers were cancer specific and not a consequence of cell line establishment.
To our knowledge, only two studies from the same group evaluated methylation markers dynamics in mCRC cases on treatment. 39 41 In their manuscript, Garrigou et al detected methylation of WIF1 and NPY by liquid biopsy in 80% mCRC, and evaluated their levels over time in cfDNA from three mCRC cases under chemotherapy treatment. 39 In a follow-up study, combining WIF1 and NPY methylation Garlan et al showed 69.2% positivity in KRAS/BRAF/ TP53 wild-type mCRC. 41 While these markers were identified by Roperch et al 21 using the Illumina GoldenGate methylation arrays (lower coverage than the Illumina Infinium), they were sorted out from our pipeline. NPY was discarded due to positivity in normal mucosa and in whole blood samples which contain white blood cells as the main contaminant of cfDNA. WIF1 instead did not satisfy our stringent threshold criteria due to limited differential methylation between normal healthy/normal adjacent mucosa and tumour. Methylation of WIF1 in normal mucosa was previously described in a small dataset 42 warranting further investigation to verify the specificity of this marker. Among other established liquid biopsy markers for CRC, SEPT9 was also filtered out from the analysis due to distance between the significantly differentially methylated probes above the 150 bp threshold.
Among the methylated loci identified in our work, EYA4 and ITGA4 are known or putative tumour suppressor genes, [43] [44] [45] [46] while the functional role of the other markers -GRIA4, MSC and MAP3K14-AS1-in carcinogenesis remains to be elucidated; however, their in silico validation in independent cohorts as well as in tissue demonstrated their reliability in identifying tumour cells.
Comparing cfDNA samples from self-declared healthy donors to patients with mCRC, all markers showed specificity above 0.85. The less efficient marker was EYA4, which demonstrated low methylated values in all donor samples. Since the signal was higher than the LOB of the assay, we hypothesised that this could be attributed to age-related methylation in normal tissue.
When evaluating plasma samples of patients with cancer, we established positivity as methylation value above a ROC threshold (allowing the best discrimination between healthy individuals and patients with cancer) and signal with positive events above the LOB. While these detection thresholds efficiently define the marker(s) to be followed over time, these assays are still suboptimal for other purposes such as early detection or minimal residual disease assesment.
Despite heterogeneity among patients, the high prevalence of at least one methylated marker warrants including these loci in a panel as a blood test for detection of plasma DNA of tumour origin in patients with stage IV CRC. In our setting, all cases with intact primary CRC in situ displayed at least one positive methylation marker, confirming that cases in which primary lesions were not resected could be more efficiently tracked through liquid biopsy.
As seen for SEPT9, 47 there was a positive correlation between cfDNA concentrations-here measured by genome equivalent per millilitre of plasma-and average methylation. However, in some samples with low total DNA content (below 20 000 genome equivalent), high methylation values were recorded; on the other hand, a subset of samples with high genome equivalent did not display detectable methylation in the selected loci. We hypothesise that these discrepancies could be explained by haemolysis during sample preparation and consequent contamination of plasma by leucocyte DNA, or by release of DNA from non-cancerous tissues during treatment, possibly due to inflammation or hepatotoxicity.
Individual markers had prevalence around 65%, and only combining the positivity of all five methylated loci resulted in 86% overall prevalence, which is slightly higher but similar to what previously reported when both NPY and WIF1 were assessed in the metastatic setting. 39 Yet, there were still 14% of mCRC cfDNA samples with undetectable circulating DNA methylation, which warrants further studies investigating possible biological or technical bases. None of the recorded clinicopathological features correlated with lack of detectable methylation levels in cfDNA. Indeed, in our limited subset of matched tissue and plasma samples, marker negativity in cfDNA was not related to low methylation value in tumour tissue DNA. Consequently, we speculate that this discordance between sample types could be attributed to spatial or temporal intratumour epigenetic heterogeneity, 48 limited DNA shedding into circulation or suboptimal plasma specimen handling.
Since tissue and microarray data displayed very low rate of non-methylated template (0% in our tissue dataset; 1.1% in microarray data), we expect that technical improvements at the detection level as well as at the DNA isolation level (eg, using higher plasma volume), will be required to achieve full penetrance of the assay. In addition to NPY and WIF1, other previously identified methylated loci in genes such as SEPT9, 16 49 VIM 19 or C9ORF50 18 are amenable to liquid biopsy analyses, and their use in combination with our panel might also improve the positivity of cfDNA detection.
One self-declared healthy donor displayed positivity in two markers and high GE content, possibly suggesting either a false-positive result or that this individual had an asymptomatic neoplastic lesion. However, the sample collection process (ie, de-identification) prevented us from verifying this hypothesis. It should be acknowledged that our digital PCR-based approach was not designed as a cancer diagnostic test, but rather optimised for its linearity and quantification ability of methylated DNA in advanced disease. Nevertheless, future studies are warranted to establish the methylation status and prevalence of the markers identified by our study in the earlier stages of colorectal neoplastic disease. This knowledge together with the development of assays that would privilege sensitivity over quantification are key to establish whether these findings could be relevant also in the setting of early detection.
There was good correlation (above 0.55) between levels of circulating DNA methylation and early genetic events in colorectal tumourigenesis such as KRAS or BRAF mutations, which validates the possibility to use methylation without prior knowledge of the Colon tumour genetic pattern, as previously shown. 39 41 Of note, four samples involved in the study were also assessed by massive parallel sequencing (data not shown) and presented genetic mutations at an allelic frequency comparable to the percentage of methylated markers, which highlights a possible role of our panel for plasma quality assessment prior to sequencing. In fact, massive parallel sequencing sometimes fails to detect tumour-specific somatic mutations due to low tumour content in cfDNA and methylation assay could therefore be used for checking tumour DNA enrichment in plasma as a quality control step.
Methylation markers in cfDNA of patients treated with EGFR inhibitors, paralleled the emergence of resistance causative genetic alterations. This finding suggests the possibility to use these methylation markers as whole tumour DNA content normaliser in plasma. This will be of particular importance when qualitative assessment (presence or absence) of individual mutation variants in the blood is not enough to predict response. Interestingly, in two cases, the likely resistance mechanism (KRAS alteration) showed very low mutant allelic frequency in comparison to the estimated amount of tumour derived cfDNA (as judged by ASM). We hypothesised that either the tumour harboured additional unknown mechanisms of resistance or a small fraction of KRAS altered cells was enough to protect the main bulk of the neoplastic lesion via paracrine effectors as previously demonstrated. 50 In two cases that progressed through emergence of a KRAS mutation, levels of mutant alleles decreased on treatment with irinotecan, independently of methylation, suggesting that the fitness of KRAS mutant clones is dependent on the presence of anti-EGFR antibodies, as previously proposed. 4 To our knowledge, very few studies evaluated longitudinally methylated cfDNA, 39 41 51 and most works essentially focused on analysis of pretreatment samples to find predictive markers of response. Here, we showed that evolution of the methylation abundance over time demonstrated good prediction of response status during treatment with conventional therapies for mCRC. This suggests that longitudinal assessment of methylation could be used in between radiological assessments for more accurate follow-up of the disease.
We were also able to retrospectively assess a batch of samples that were collected in a clinical trial with temozolomide for the treatment of chemorefractory mCRC. Samples were not collected with the aim to directly compare cfDNA with CT scans. Imaging was not usually performed at the very same time-points when blood was drawn. Despite this limitation and the low response rate of mCRC on temozolomide treatment, dynamics of methylation could predict clinical benefit. This implicates that the monitoring of methylated circulating DNA might be used as a surrogate to imaging in order to evaluate treatment efficacy and might help reducing delays in therapeutic reorientation. In fact, with the emergence of concepts such as early tumour shrinkage associated with long-term outcome, 52 53 short-term evaluation of pharmacodynamic response using liquid biopsy might become common practice.
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